Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Novello

Showing results (771-780 of 1,095) with videos related to

Pageof 110
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine aloneS Novello, P Bruzzi, C Barone, et al.
Drug Safety|December 20, 2021
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and ManageabilityErnest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trialRodryg Ramlau, Vera Gorbunova, Tudor Eliade Ciuleanu, et al.
Neurosurgical Review|October 29, 2024
The role of surgery in recurrent local cerebral metastases: a multi-institutional retrospective analysisStefano Telera, Luigino Tosatto, Roberto Colasanti, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2019
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinionLizza E L Hendriks, Christophe Dooms, Thierry Berghmans, et al.
Future Oncology (London, England)|December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i>-mutated NSCLC after a third-generation EGFR TKITony Mok, Pasi A Jänne, Makoto Nishio, et al.
JTO Clinical and Research Reports|June 26, 2025
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Silvia Novello, Pilar Garrido, et al.
The American Journal of Pathology|January 13, 2011
Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysisAmalia Conti, Gemma Caballero Rodriguez, Antonella Chiechi, et al.
British Journal of Pharmacology|December 13, 2017
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonistsLudovico Arcuri, Salvatore Novello, Martina Frassineti, et al.
Micromachines|January 20, 2019
Progress in the Field of Micro-ElectrocorticographyMehdi Shokoueinejad, Dong-Wook Park, Yei Hwan Jung, et al.
Pageof 110

Showing results (771-780 of 1,095) with videos related to

Sort By:
Pageof 110
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 14, 2007
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine aloneS Novello, P Bruzzi, C Barone, et al.
Drug Safety|December 20, 2021
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and ManageabilityErnest Nadal, Hidehito Horinouchi, Jin-Yuan Shih, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2012
Aflibercept and Docetaxel versus Docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trialRodryg Ramlau, Vera Gorbunova, Tudor Eliade Ciuleanu, et al.
Neurosurgical Review|October 29, 2024
The role of surgery in recurrent local cerebral metastases: a multi-institutional retrospective analysisStefano Telera, Luigino Tosatto, Roberto Colasanti, et al.
European Journal of Cancer (Oxford, England : 1990)|October 27, 2019
Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinionLizza E L Hendriks, Christophe Dooms, Thierry Berghmans, et al.
Future Oncology (London, England)|December 14, 2023
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i>-mutated NSCLC after a third-generation EGFR TKITony Mok, Pasi A Jänne, Makoto Nishio, et al.
JTO Clinical and Research Reports|June 26, 2025
Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in <i>RET</i> Fusion-Positive NSCLCCaicun Zhou, Silvia Novello, Pilar Garrido, et al.
The American Journal of Pathology|January 13, 2011
Identification of potential biomarkers for giant cell tumor of bone using comparative proteomics analysisAmalia Conti, Gemma Caballero Rodriguez, Antonella Chiechi, et al.
British Journal of Pharmacology|December 13, 2017
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonistsLudovico Arcuri, Salvatore Novello, Martina Frassineti, et al.
Micromachines|January 20, 2019
Progress in the Field of Micro-ElectrocorticographyMehdi Shokoueinejad, Dong-Wook Park, Yei Hwan Jung, et al.
Pageof 110